This trial will demonstrate localised uptake of a radiolabelled fungal component (siderophore) in areas of known specific invasive fungal (Aspergillus) infection.
Patient has provided written informed consent
Aged 18 years or older at written informed consent
Within 2 weeks of proven or probable or possible invasive fungal infection (IFI) diagnosis as per EORTC criteria
Imaging consistent with invasive pulmonary aspergillosis on CT or FDG-PET/CT with lesions at least 8mm in diameter
Women who are pregnant or lactating.
Iron infusion within one week prior to scan
Patients aged 18 years or older at written informed consent who have proven or probable invasive fungal infection (IFI) diagnosis with imaging consistent with invasive pulmonary aspergillosis on CT or FDG-PET/CT with lesions at least 8mm in diameter. They are also willing and able to comply with the protocol for the duration of the study including scheduled visits such as follow up.
Cohort
Prospective
68Ga-labelled TAFC PET/CT scan
Diagnostic test68Ga-labelled TAFC PET/CT scan (whole body)
Uptake of radiolabelled siderophore (68Ga-TAFC) in patients with proven/probable invasive Aspergillosis
The maximum standardized uptake value (SUVmax) is widely used for measuring the uptake of FDG by malignant tissue.
Physiologic bio distribution
SUVmax in mediastinal blood pool, and any organs with uptake including liver, spleen and marrow
Safety of 68Ga-TAFC-PET/CT
Adverse events defined by CTCAE v5
Findings compared to CT and/or 18F-FDG PET/CT
Descriptive comparison of the siderophore PET to standard of care imaging - looking at areas of uptake and if this corresponds to areas of presumed infection on SOC PET or CT
Click on the lead sponsor to view all of their trials.
